- Home
- TAK
as 11-15-2024 4:00pm EST
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
| Founded: | 1781 | Country: | Japan |
| Employees: | N/A | City: | N/A |
| Market Cap: | 43.9B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 1.27 | EPS Growth: | 49.73 |
| 52 Week Low/High: | $12.58 - $15.08 | Next Earning Date: | 10-31-2024 |
| Revenue: | $31,732,209,416 | Revenue Growth: | 9.43% |
| Revenue Growth (this year): | 4.41% | Revenue Growth (next year): | 1.09% |
Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) News
TAK Breaking Stock News: Dive into TAK Ticker-Specific Updates for Smart Investing
Fortune
4 days ago
Why this major drugmaker no longer has an ‘IT department’
CNW Group
13 days ago
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD
MT Newswires
17 days ago
HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales
MT Newswires
18 days ago
Takeda Pharmaceutical's Fiscal Q2 Core Earnings, Revenue Increase; Fiscal-Year Outlook Raised
GlobeNewswire
18 days ago
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
Business Wire
18 days ago
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
GuruFocus.com
18 days ago
What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings
Pharmaceutical Technology
23 days ago
Takeda and BMC partner to decarbonise US healthcare sector
Compare TAK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.